Maximus vs bmiMD: Semaglutide vs Tirzepatide Pricing Guide
Comparing Maximus vs bmiMD: Maximus focuses on low, flat-rate compounded semaglutide starting at $132.99 per month with telemedicine and free expedited shipping, while bmiMD offers compounded tirzepatide with multi-month plans that reduce the monthly equivalent to as low as $139 per month. Early verdict: pick Maximus if you want a straightforward, lower flat monthly price for semaglutide; pick bmiMD if you want tirzepatide and are willing to commit to a longer billing term for the lowest monthly equivalent.
Get Maximus semaglutide pricing
Key differences at a glance
This comparison centers on five distinctive differences: medication offered, starting price and billing options, telemedicine and clinician access, shipping and fulfillment, and compounded regulatory notes.
Medication type: semaglutide versus tirzepatide
Maximus provides compounded semaglutide for once-weekly GLP-1 injections. bmiMD offers compounded tirzepatide, a GLP-1/GIP option. The two providers therefore target different active medications; choose based on which molecule you have discussed with a clinician. The source notes that both providers offer compounded medications, and that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
Pricing and billing structure
Maximus advertises a low flat rate with statements like $132.99 per month and references to starting at $79.99 in captured landing-page text. Maximus operates as a direct-pay model with no insurance billing and highlights transparent monthly pricing.
See Maximus direct-pay details
bmiMD lists four billing options: month-to-month at $179 per month, a three-month plan at $159 per month, a six-month plan at $149 per month, and a 12-month plan at $139 per month. bmiMD highlights that the lowest monthly equivalent requires a 12-month commitment and asks users to confirm total prepaid charges and eligibility before enrollment.
Telemedicine, clinician access, and refill process
Maximus emphasizes convenient telemedicine access, prescriptions approved by licensed doctors, and filling through trusted U.S. pharmacies with no in-person clinic visits required. bmiMD advertises clinician-reviewed online treatment with 24/7 clinician access and online refills and delivery. Both require a licensed clinician to determine medical appropriateness for treatment.
Shipping, fulfillment, and guarantees
Maximus indicates free priority or expedited shipping and a refund of medication costs if not approved for treatment. bmiMD offers free shipping on every subscription order and states a 100 percent refund if a person is not eligible for the program. Each provider notes that medication is prepared in pharmacies; bmiMD adds that medications are prepared in state-licensed pharmacies and independently verified in certain labs according to the captured landing-page evidence.
Side note: compounded medication regulatory status
Both sources explicitly state that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. That regulatory note is part of each provider’s captured information and should factor into decision making.
Comparison table
| Criteria | Maximus | bmiMD |
|---|---|---|
| Primary medication | Compounded semaglutide | Compounded tirzepatide (GLP-1/GIP) |
| Starting monthly price | $132.99 per month advertised | $179 month-to-month; as low as $139/month with 12-month plan |
| Billing options | Direct-pay flat rate, no membership | 1, 3, 6, 12 month plans with lower long-term equivalent |
| Clinician access | Prescriptions approved by licensed doctors, telemedicine | Clinician-reviewed online treatment, 24/7 clinician access |
| Shipping and refunds | Free expedited shipping; refund if not approved | Free shipping on subscriptions; 100 percent refundable if not eligible |
| Regulatory note | Compounded medicines not FDA-approved | Compounded medicines not FDA-approved |
Final comparison and how to choose
Maximus vs bmiMD comes down to medication choice and billing preference. Maximus is positioned as a lower flat monthly option for compounded semaglutide with straightforward telemedicine and U.S. pharmacy fulfillment. bmiMD focuses on compounded tirzepatide with multiple billing terms where the lowest monthly equivalent requires a longer commitment and prepaid total should be confirmed.
Compare bmiMD tirzepatide plans
Choose Maximus if…
you want compounded semaglutide via telemedicine with a low flat monthly price advertised at $132.99 per month, prescriptions approved by licensed doctors, and U.S. pharmacy fulfillment with free expedited shipping.
Start with Maximus semaglutide
Choose bmiMD if…
you prefer compounded tirzepatide and want the option to lower your monthly equivalent by choosing a 6 or 12 month plan, understand the required commitment and total prepaid charge, and value 24/7 clinician access and subscription shipping.
Both providers note that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. If additional details such as state availability or exact prepaid totals matter, consult each provider directly as those specifics are captured in the original source material.